Horizon Pharma plc (HZNP) : During the past 4 weeks, traders have been relatively bearish on Horizon Pharma plc (HZNP), hence the stock is down -11.13% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -8.64% relative to the S&P 500. The 4-week change in the price of the stock is -11.24% and the stock has fallen -8.18% in the past 1 week.
The stock has recorded a 20-day Moving Average of 16.19% and the 50-Day Moving Average is 8.45%.The 200 Day SMA reached 1.57%. Horizon Pharma plc has dropped 5.21% during the last 3-month period . Year-to-Date the stock performance stands at -17.67%.
Horizon Pharma plc (NASDAQ:HZNP): The stock opened in the green at $18.71 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $18.96 and a low of $17.68 for the day. The stock did not find buyers even at the lows and closed at $17.84 recording a loss of -4.19%. 4,359,448 shares exchanged hands during the trading day. The stock had closed at $18.62 in the previous days trading.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.